Your session is about to expire
← Back to Search
Memantine for Cognitive Improvement in Schizophrenia
Phase 2 & 3
Recruiting
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 25 weeks
Awards & highlights
Study Summary
This trial is testing whether the drug memantine can help people with schizophrenia by improving their cognitive functioning.
Who is the study for?
This trial is for adults aged 18-65 with schizophrenia or schizoaffective disorder, who can understand and communicate in English. They must not have dementia, mental retardation, current drug abuse issues, severe sensory impairments, traumatic brain injury, or be pregnant.Check my eligibility
What is being tested?
The study tests if Memantine can boost the effects of targeted cognitive training (TCT) in improving cognitive functions in schizophrenia patients. Participants will either receive Memantine or a placebo alongside TCT sessions and are randomly assigned to these groups.See study design
What are the potential side effects?
Memantine may cause side effects like dizziness, headache, confusion, constipation. It's also possible to experience more serious effects such as shortness of breath or an allergic reaction.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 25 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~25 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Clinical symptoms
MCCB cognitive test performance
Sound Sweeps and perceptual learning
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: TCT + MEMActive Control1 Intervention
Suppressing active psychosis with antipsychotics benefits cognitive interventions for schizophrenia, but it is possible that drugs with pro-cognitive effects will specifically, and perhaps synergistically, augment the clinical benefits of cognitive therapies. A "proof of concept" for this approach is found in the use of the pro-extinction drugs to selectively enhance the impact of cognitive therapy for anxiety disorders. In this "proof of concept", a learning-based therapy is paired with a medication that enhances a brain mechanism (extinction) that is both 1) critical to that form of learning, and 2) known to be deficient in some anxiety disorders.
Group II: TCT + PBOPlacebo Group1 Intervention
Suppressing active psychosis with antipsychotics benefits cognitive interventions for schizophrenia, but it is possible that drugs with pro-cognitive effects will specifically, and perhaps synergistically, augment the clinical benefits of cognitive therapies. A "proof of concept" for this approach is found in the use of the pro-extinction drugs to selectively enhance the impact of cognitive therapy for anxiety disorders. In this "proof of concept", a learning-based therapy is paired with a medication that enhances a brain mechanism (extinction) that is both 1) critical to that form of learning, and 2) known to be deficient in some anxiety disorders.
Find a Location
Who is running the clinical trial?
University of California, San DiegoLead Sponsor
1,120 Previous Clinical Trials
1,521,566 Total Patients Enrolled
27 Trials studying Schizophrenia
5,833 Patients Enrolled for Schizophrenia
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You cannot participate in the study if you have significant hearing or vision problems.You are pregnant.You have problems with drug or alcohol addiction right now and have not been sober for at least 30 days.You have experienced a serious injury to your head in the past.You have been diagnosed with schizophrenia or schizoaffective disorder according to a specific set of criteria.
Research Study Groups:
This trial has the following groups:- Group 1: TCT + PBO
- Group 2: TCT + MEM
Awards:
This trial has 2 awards, including:- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What other research has been conducted on the effectiveness of TCT + MEM?
"At this time, there are 26 TCT + MEM trials. Out of these, 11 are in Phase 3. Although a majority of the TCT + MEM trials are based in Geneva, Illinois, there are a total of 290 locations running these trials."
Answered by AI
Are elderly people able to participate in this medical study?
"This particular clinical trial is only accepting applications from people who are between 18-65 years old. However, there are 99 other trials that are accepting patients who are under 18 and 240 trials for seniors."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger